Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Long-Term Deferred Tax (2016 - 2025)

Historic Long-Term Deferred Tax for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $71.1 million.

  • Amphastar Pharmaceuticals' Long-Term Deferred Tax rose 3356.12% to $71.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.1 million, marking a year-over-year increase of 3356.12%. This contributed to the annual value of $71.1 million for FY2024, which is 3356.12% up from last year.
  • According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' Long-Term Deferred Tax is $71.1 million, which was up 3356.12% from $71.1 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' Long-Term Deferred Tax's 5-year high stood at $71.1 million during Q4 2024, with a 5-year trough of $22.0 million in Q3 2021.
  • Its 5-year average for Long-Term Deferred Tax is $43.0 million, with a median of $40.9 million in 2023.
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first crashed by 1033.23% in 2021, then surged by 8245.46% in 2023.
  • Quarter analysis of 5 years shows Amphastar Pharmaceuticals' Long-Term Deferred Tax stood at $22.4 million in 2021, then soared by 72.0% to $38.5 million in 2022, then surged by 38.22% to $53.3 million in 2023, then skyrocketed by 33.56% to $71.1 million in 2024, then changed by 0.0% to $71.1 million in 2025.
  • Its last three reported values are $71.1 million in Q3 2025, $71.1 million for Q2 2025, and $71.1 million during Q1 2025.